

# Antonio Oliver

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2072871/publications.pdf>

Version: 2024-02-01

321  
papers

21,252  
citations

11235

73  
h-index

16186

128  
g-index

351  
all docs

351  
docs citations

351  
times ranked

21232  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparative analysis of <i>in vitro</i> dynamics and mechanisms of ceftolozane/tazobactam and imipenem/relebactam resistance development in <i>Pseudomonas aeruginosa</i> XDR high-risk clones. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 957-968.	1.3	14
2	Boosting the sensitivity of paper-based biosensors with polymeric water-soluble reservoirs. <i>Sensors and Actuators B: Chemical</i> , 2022, 354, 131214.	4.0	4
3	Simulated Intravenous versus Inhaled Tobramycin with or without Intravenous Ceftazidime Evaluated against Hypermutable <i>Pseudomonas aeruginosa</i> via a Dynamic Biofilm Model and Mechanism-Based Modeling. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, aac0220321.	1.4	4
4	Mammals' humoral immune proteins and peptides targeting the bacterial envelope: from natural protection to therapeutic applications against multidrug-resistant Gram-negatives. <i>Biological Reviews</i> , 2022, 97, 1005-1037.	4.7	5
5	Selection of AmpC $\beta$ -Lactamase Variants and Metallo- $\beta$ -Lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/XDR <i>Pseudomonas aeruginosa</i> Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0206721.	1.4	28
6	Impact of Peptidoglycan Recycling Blockade and Expression of Horizontally Acquired $\beta$ -Lactamases on <i>Pseudomonas aeruginosa</i> Virulence. <i>Microbiology Spectrum</i> , 2022, 10, e0201921.	1.2	8
7	Susceptibility profiles and resistance genomics of <i>Pseudomonas aeruginosa</i> isolates from European ICUs participating in the ASPIRE-ICU trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1862-1872.	1.3	23
8	Rapid Identification and Classification of Pathogens That Produce Carbapenemases and Cephalosporinases with a Colorimetric Paper-Based Multisensor. <i>Analytical Chemistry</i> , 2022, 94, 9442-9449.	3.2	8
9	Recommendations of the Spanish Antibiogram Committee (COESANT) for <i>in vitro</i> susceptibility testing of antimicrobial agents by disk diffusion. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2022, , .	0.3	0
10	<i>In vivo</i> translational assessment of the GES genotype on the killing profile of ceftazidime, ceftazidime/avibactam and meropenem against <i>Pseudomonas aeruginosa</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 2803-2808.	1.3	7
11	Molecular mechanisms driving the <i>in vivo</i> development of OXA-10-mediated resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of XDR <i>Pseudomonas aeruginosa</i> infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 91-100.	1.3	38
12	Bedside Detection of Carbapenemase-Producing Pathogens with Plasmonic Nanosensors. <i>Sensors and Actuators B: Chemical</i> , 2021, 329, 129059.	4.0	10
13	Distinct epidemiology and resistance mechanisms affecting ceftolozane/tazobactam in <i>Pseudomonas aeruginosa</i> isolates recovered from ICU patients in Spain and Portugal depicted by WGS. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 370-379.	1.3	14
14	Optimized detection of lung IL-6 via enzymatic liquefaction of low respiratory tract samples: application for managing ventilated patients. <i>Analyst</i> , 2021, 146, 6537-6546.	1.7	2
15	Panbio <sup>®</sup> rapid antigen test for SARS-CoV-2 has acceptable accuracy in symptomatic patients in primary health care. <i>Journal of Infection</i> , 2021, 82, 391-398.	1.7	53
16	Molecular Basis of AmpC $\beta$ -Lactamase Induction by Avibactam in <i>Pseudomonas aeruginosa</i> : PBP Occupancy, Live Cell Binding Dynamics and Impact on Resistant Clinical Isolates Harboring PDC-X Variants. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3051.	1.8	7
17	Immunodetection of Lung IgG and IgM Antibodies against SARS-CoV-2 via Enzymatic Liquefaction of Respiratory Samples from COVID-19 Patients. <i>Analytical Chemistry</i> , 2021, 93, 5259-5266.	3.2	8
18	6-Halopyridylmethylidene Penicillin-Based Sulfones Efficiently Inactivate the Natural Resistance of <i>Pseudomonas aeruginosa</i> to $\beta$ -Lactam Antibiotics. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 6310-6328.	2.9	10

#	ARTICLE	IF	CITATIONS
19	Rapid evolution and host immunity drive the rise and fall of carbapenem resistance during an acute <i>Pseudomonas aeruginosa</i> infection. <i>Nature Communications</i> , 2021, 12, 2460.	5.8	47
20	<i>Pseudomonas aeruginosa</i> : a clinical and genomics update. <i>FEMS Microbiology Reviews</i> , 2021, 45, .	3.9	26
21	Use of Matrix-Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry Analysis of Serum Peptidome to Classify and Predict Coronavirus Disease 2019 Severity. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab222.	0.4	3
22	Combination versus monotherapy as definitive treatment for <i>Pseudomonas aeruginosa</i> bacteraemia: a multicentre retrospective observational cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2172-2181.	1.3	19
23	Metagenomics Analysis Reveals an Extraordinary Inner Bacterial Diversity in Anisakids (Nematoda: Tj ETQq1 1 0.784314 rgBT <sub>4</sub> /Overlook	1.6	4
24	Predicting <i>Pseudomonas aeruginosa</i> susceptibility phenotypes from whole genome sequence resistome analysis. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1631-1637.	2.8	36
25	Validation of MALDI-TOF for the early detection of the ST175 high-risk clone of <i>Pseudomonas aeruginosa</i> in clinical isolates belonging to a Spanish nationwide multicenter study. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2021, 39, 279-282.	0.3	4
26	Spread of a SARS-CoV-2 variant through Europe in the summer of 2020. <i>Nature</i> , 2021, 595, 707-712.	13.7	363
27	Validation of MALDI-TOF for the early detection of the ST175 high-risk clone of <i>Pseudomonas aeruginosa</i> in clinical isolates belonging to a Spanish nationwide multicenter study. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2021, 39, 279-282.	0.2	2
28	<i>In vitro</i> evolution of cefepime/zidebactam (WCK 5222) resistance in <i>Pseudomonas aeruginosa</i> : dynamics, mechanisms, fitness trade-off and impact on <i>in vivo</i> efficacy. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2546-2557.	1.3	11
29	Emergence of Resistance to Novel Cephalosporin-β-Lactamase Inhibitor Combinations through the Modification of the <i>Pseudomonas aeruginosa</i> MexCD-OprJ Efflux Pump. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0008921.	1.4	29
30	Predictive Immunological, Virological, and Routine Laboratory Markers for Critical COVID-19 on Admission. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2021, 2021, 1-8.	0.7	7
31	<i>In Vivo</i> Evolution of GES-2-Lactamases Driven by Ceftazidime/Avibactam Treatment of <i>Pseudomonas aeruginosa</i> Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0098621.	1.4	14
32	Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant <i>Pseudomonas aeruginosa</i> and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates. <i>Microbiology Spectrum</i> , 2021, 9, e0058521.	1.2	18
33	The first wave of the COVID-19 epidemic in Spain was associated with early introductions and fast spread of a dominating genetic variant. <i>Nature Genetics</i> , 2021, 53, 1405-1414.	9.4	35
34	Pharmacodynamics of ceftazidime plus tobramycin combination dosage regimens against hypermutable <i>Pseudomonas aeruginosa</i> isolates at simulated epithelial lining fluid concentrations in a dynamic <i>in vitro</i> infection model. <i>Journal of Global Antimicrobial Resistance</i> , 2021, 26, 55-63.	0.9	7
35	Recommendations for antibiotic selection for severe nosocomial infections. <i>Revista Espanola De Quimioterapia</i> , 2021, 34, 511-524.	0.5	8
36	A Large Multicenter Prospective Study of Community-Onset Healthcare Associated Bacteremic Urinary Tract Infections in the Era of Multidrug Resistance: Even Worse than Hospital Acquired Infections?. <i>Infectious Diseases and Therapy</i> , 2021, 10, 2677-2699.	1.8	4

#	ARTICLE	IF	CITATIONS
37	Whole-genome sequence-guided PCR for the rapid identification of the <i>Pseudomonas aeruginosa</i> ST175 high-risk clone directly from clinical samples. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 945-949.	1.3	2
38	<i>Pseudomonas aeruginosa</i> Susceptibility in Spain: Antimicrobial Activity and Resistance Suppression Evaluation by PK/PD Analysis. <i>Pharmaceutics</i> , 2021, 13, 1899.	2.0	5
39	Inhaled corticosteroid use and its association with <i>Pseudomonas aeruginosa</i> infection in COPD. , 2021, , .		0
40	Impact of ceftolozane/tazobactam concentrations in continuous infusion against extensively drug-resistant <i>Pseudomonas aeruginosa</i> isolates in a hollow-fiber infection model. <i>Scientific Reports</i> , 2021, 11, 22178.	1.6	6
41	A Genomic Snapshot of the SARS-CoV-2 Pandemic in the Balearic Islands. <i>Frontiers in Microbiology</i> , 2021, 12, 803827.	1.5	3
42	Multicenter Performance Evaluation of MALDI-TOF MS for Rapid Detection of Carbapenemase Activity in Enterobacterales: The Future of Networking Data Analysis With Online Software. <i>Frontiers in Microbiology</i> , 2021, 12, 789731.	1.5	4
43	Molecular Analysis of the Contribution of Alkaline Protease A and Elastase B to the Virulence of <i>Pseudomonas aeruginosa</i> Bloodstream Infections. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 816356.	1.8	7
44	Del CLSI al EUCAST, una transición necesaria en los laboratorios españoles. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2020, 38, 79-83.	0.3	11
45	Long-term Persistence of an Extensively Drug-Resistant Subclade of Globally Distributed <i>Pseudomonas aeruginosa</i> Clonal Complex 446 in an Academic Medical Center. <i>Clinical Infectious Diseases</i> , 2020, 71, 1524-1531.	2.9	20
46	Weighting the impact of virulence on the outcome of <i>Pseudomonas aeruginosa</i> bloodstream infections. <i>Clinical Microbiology and Infection</i> , 2020, 26, 351-357.	2.8	11
47	Ceftazidime, Carbapenems, or Piperacillin-tazobactam as Single Definitive Therapy for <i>Pseudomonas aeruginosa</i> Bloodstream Infection: A Multisite Retrospective Study. <i>Clinical Infectious Diseases</i> , 2020, 70, 2270-2280.	2.9	24
48	A Standard Numbering Scheme for Class C $\beta$ -Lactamases. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	50
49	From CLSI to EUCAST, a necessary step in Spanish laboratories. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2020, 38, 79-83.	0.2	2
50	Minimum information guideline for spectrophotometric and fluorometric methods to assess biofilm formation in microplates. <i>Biofilm</i> , 2020, 2, 100010.	1.5	50
51	Pathogenic characteristics of <i>Pseudomonas aeruginosa</i> bacteraemia isolates in a high-endemicity setting for ST175 and ST235 high-risk clones. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2020, 39, 671-678.	1.3	15
52	Emergence of high-level and stable metronidazole resistance in <i>Clostridioides difficile</i> . <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105830.	1.1	4
53	Risk factors for mortality among patients with <i>Pseudomonas aeruginosa</i> bacteraemia: a retrospective multicentre study. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105847.	1.1	33
54	<i>Pseudomonas aeruginosa</i> epidemic high-risk clones and their association with horizontally-acquired $\beta$ -lactamases: 2020 update. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106196.	1.1	147

#	ARTICLE	IF	CITATIONS
55	Mobile origami immunosensors for the rapid detection of urinary tract infections. <i>Analyst</i> , The, 2020, 145, 7916-7921.	1.7	11
56	Adding Insult to Injury: Mechanistic Basis for How AmpC Mutations Allow <i>Pseudomonas aeruginosa</i> To Accelerate Cephalosporin Hydrolysis and Evade Avibactam. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	27
57	Recommendations of the Spanish Antibiogram Committee (COESANT) for selecting antimicrobial agents and concentrations for in vitro susceptibility studies using automated systems. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2020, 38, 182-187.	0.2	0
58	Rapid Detection of <i>Pseudomonas aeruginosa</i> Biofilms via Enzymatic Liquefaction of Respiratory Samples. <i>ACS Sensors</i> , 2020, 5, 3956-3963.	4.0	17
59	Molecular and biochemical insights into the in vivo evolution of AmpC-mediated resistance to ceftolozane/tazobactam during treatment of an MDR <i>Pseudomonas aeruginosa</i> infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3209-3217.	1.3	26
60	WGS characterization of MDR Enterobacterales with different ceftolozane/tazobactam susceptibility profiles during the SUPERIOR surveillance study in Spain. <i>JAC-Antimicrobial Resistance</i> , 2020, 2, dlaa084.	0.9	7
61	Temperate Bacteriophages (Prophages) in <i>Pseudomonas aeruginosa</i> Isolates Belonging to the International Cystic Fibrosis Clone (CC274). <i>Frontiers in Microbiology</i> , 2020, 11, 556706.	1.5	18
62	A Genome-Based Model to Predict the Virulence of <i>Pseudomonas aeruginosa</i> Isolates. <i>MBio</i> , 2020, 11, .	1.8	12
63	Clinically Relevant Epithelial Lining Fluid Concentrations of Meropenem with Ciprofloxacin Provide Synergistic Killing and Resistance Suppression of Hypermutable <i>Pseudomonas aeruginosa</i> in a Dynamic Biofilm Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	7
64	Efficacy of Ceftolozane-Tazobactam in Combination with Colistin against Extensively Drug-Resistant <i>Pseudomonas aeruginosa</i> , Including High-Risk Clones, in an <i>In Vitro</i> Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	8
65	Nosocomial outbreak linked to a flexible gastrointestinal endoscope contaminated with an amikacin-resistant ST17 clone of <i>Pseudomonas aeruginosa</i> . <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2020, 39, 1837-1844.	1.3	11
66	Carbapenemase-producing <i>Pseudomonas aeruginosa</i> in Spain: interregional dissemination of the high-risk clones ST175 and ST244 carrying blaVIM-2, blaVIM-1, blaIMP-8, blaVIM-20 and blaKPC-2. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106026.	1.1	27
67	In vitro dynamics and mechanisms of resistance development to imipenem and imipenem/relebactam in <i>Pseudomonas aeruginosa</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2508-2515.	1.3	24
68	Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. <i>Lancet</i> , The, 2020, 396, 535-544.	6.3	1,465
69	Activity of Imipenem-Relebactam against a Large Collection of <i>Pseudomonas aeruginosa</i> Clinical Isolates and Isogenic $\beta$ -Lactam-Resistant Mutants. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	54
70	Effective inhibition of PBPs by cefepime and zidebactam in the presence of VIM-1 drives potent bactericidal activity against MBL-expressing <i>Pseudomonas aeruginosa</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1474-1478.	1.3	26
71	In vitro and in vivo efficacy of combinations of colistin and different endolysins against clinical strains of multi-drug resistant pathogens. <i>Scientific Reports</i> , 2020, 10, 7163.	1.6	54
72	Characterization of AmpC $\beta$ -lactamase mutations of extensively drug-resistant <i>Pseudomonas aeruginosa</i> isolates that develop resistance to ceftolozane/tazobactam during therapy. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2020, 38, 474-478.	0.3	13

#	ARTICLE	IF	CITATIONS
73	Predicting antimicrobial resistance in <i>Pseudomonas aeruginosa</i> with machine learning-enabled molecular diagnostics. <i>EMBO Molecular Medicine</i> , 2020, 12, e10264.	3.3	111
74	Recommendations of the Spanish Antibiogram Committee (COESANT) for selecting antimicrobial agents and concentrations for in vitro susceptibility studies using automated systems. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2020, 38, 182-187.	0.3	6
75	Characterization of AmpC $\beta$ -lactamase mutations of extensively drug-resistant <i>Pseudomonas aeruginosa</i> isolates that develop resistance to ceftolozane/tazobactam during therapy. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2020, 38, 474-478.	0.2	1
76	Activity of mammalian peptidoglycan-targeting immunity against <i>Pseudomonas aeruginosa</i> . <i>Journal of Medical Microbiology</i> , 2020, 69, 492-504.	0.7	5
77	Role of inhaled corticosteroids on recurrent bronchial infection by potentially pathogenic bacteria in patients with COPD. , 2020, , .		0
78	Four Decades of $\beta$ -Lactam Antibiotic Pharmacokinetics in Cystic Fibrosis. <i>Clinical Pharmacokinetics</i> , 2019, 58, 143-156.	1.6	15
79	Association between <i>Pseudomonas aeruginosa</i> O-antigen serotypes, resistance profiles and high-risk clones: results from a Spanish nationwide survey. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3217-3220.	1.3	18
80	Synergistic Meropenem-Tobramycin Combination Dosage Regimens against Clinical Hypermutable <i>Pseudomonas aeruginosa</i> at Simulated Epithelial Lining Fluid Concentrations in a Dynamic Biofilm Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	11
81	Challenging Antimicrobial Susceptibility and Evolution of Resistance (OXA-681) during Treatment of a Long-Term Nosocomial Infection Caused by a <i>Pseudomonas aeruginosa</i> ST175 Clone. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	22
82	Therapeutic Efficacy of LN-1-255 in Combination with Imipenem in Severe Infection Caused by Carbapenem-Resistant <i>Acinetobacter baumannii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	9
83	In Vivo Validation of Peptidoglycan Recycling as a Target to Disable AmpC-Mediated Resistance and Reduce Virulence Enhancing the Cell-Wall-Targeting Immunity. <i>Journal of Infectious Diseases</i> , 2019, 220, 1729-1737.	1.9	18
84	Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant <i>Pseudomonas aeruginosa</i> Infections. <i>Clinical Microbiology Reviews</i> , 2019, 32, .	5.7	489
85	Comparative Analysis of Peptidoglycans From <i>Pseudomonas aeruginosa</i> Isolates Recovered From Chronic and Acute Infections. <i>Frontiers in Microbiology</i> , 2019, 10, 1868.	1.5	12
86	Evaluation of Tobramycin and Ciprofloxacin as a Synergistic Combination Against Hypermutable <i>Pseudomonas Aeruginosa</i> Strains via Mechanism-Based Modelling. <i>Pharmaceutics</i> , 2019, 11, 470.	2.0	4
87	Higher MICs ( $\geq 2$ mg/L) Predict 30-Day Mortality in Patients With Lower Respiratory Tract Infections Caused by Multidrug- and Extensively Drug-Resistant <i>Pseudomonas aeruginosa</i> Treated With Ceftolozane/Tazobactam. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz416.	0.4	22
88	O-antigen serotyping and MALDI-TOF, potentially useful tools for optimizing semi-empiric antipseudomonal treatments through the early detection of high-risk clones. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2019, 38, 541-544.	1.3	17
89	Colistin plus meropenem combination is synergistic in vitro against extensively drug-resistant <i>Pseudomonas aeruginosa</i> , including high-risk clones. <i>Journal of Global Antimicrobial Resistance</i> , 2019, 18, 37-44.	0.9	16
90	Spanish nationwide survey on <i>Pseudomonas aeruginosa</i> antimicrobial resistance mechanisms and epidemiology. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1825-1835.	1.3	92

#	ARTICLE	IF	CITATIONS
91	Profiling the susceptibility of <i>Pseudomonas aeruginosa</i> strains from acute and chronic infections to cell-wall-targeting immune proteins. <i>Scientific Reports</i> , 2019, 9, 3575.	1.6	10
92	Social Behavior of Antibiotic Resistant Mutants Within <i>Pseudomonas aeruginosa</i> Biofilm Communities. <i>Frontiers in Microbiology</i> , 2019, 10, 570.	1.5	21
93	<i>In Vitro</i> and <i>In Vivo</i> Activities of $\beta$ -Lactams in Combination with the Novel $\beta$ -Lactam Enhancers Zidebactam and WCK 5153 against Multidrug-Resistant Metallo- $\beta$ -Lactamase-Producing <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	35
94	Characterization of Hypermutator <i>Pseudomonas aeruginosa</i> Isolates from Patients with Cystic Fibrosis in Australia. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	30
95	Regulation of AmpC-Driven $\beta$ -Lactam Resistance in <i>Pseudomonas aeruginosa</i> : Different Pathways, Different Signaling. <i>MSystems</i> , 2019, 4, .	1.7	53
96	Emergence of Resistance to Novel $\beta$ -Lactam- $\beta$ -Lactamase Inhibitor Combinations Due to Horizontally Acquired AmpC (FOX-4) in <i>Pseudomonas aeruginosa</i> Sequence Type 308. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 64, .	1.4	10
97	Identifying and exploiting genes that potentiate the evolution of antibiotic resistance. <i>Nature Ecology and Evolution</i> , 2018, 2, 1033-1039.	3.4	41
98	Comparison of Predictors and Mortality Between Bloodstream Infections Caused by ESBL-Producing <i>Escherichia coli</i> and ESBL-Producing <i>Klebsiella pneumoniae</i> . <i>Infection Control and Hospital Epidemiology</i> , 2018, 39, 660-667.	1.0	49
99	Optimization of a Meropenem-Tobramycin Combination Dosage Regimen against Hypermutable and Nonhypermutable <i>Pseudomonas aeruginosa</i> via Mechanism-Based Modeling and the Hollow-Fiber Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	31
100	Phenylboronic Acid Derivatives as Validated Leads Active in Clinical Strains Overexpressing KPC $\beta$ : A Step against Bacterial Resistance. <i>ChemMedChem</i> , 2018, 13, 713-724.	1.6	24
101	Evolution of the <i>Pseudomonas aeruginosa</i> Aminoglycoside Mutational Resistome <i>In Vitro</i> and in the Cystic Fibrosis Setting. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	44
102	Mechanisms leading to <i>in vivo</i> ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR <i>Pseudomonas aeruginosa</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 658-663.	1.3	157
103	Evaluation of Ceftolozane-Tazobactam in Combination with Meropenem against <i>Pseudomonas aeruginosa</i> Sequence Type 175 in a Hollow-Fiber Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	21
104	Increased Antimicrobial Resistance in a Novel CMY-54 AmpC-Type Enzyme with a GluLeu <sup>217</sup> $\beta$ <sup>218</sup> Insertion in the $\beta$ -Loop. <i>Microbial Drug Resistance</i> , 2018, 24, 527-533.	0.9	4
105	Use of Calgary and Microfluidic BioFlux Systems To Test the Activity of Fosfomicin and Tobramycin Alone and in Combination against Cystic Fibrosis <i>Pseudomonas aeruginosa</i> Biofilms. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	21
106	Antimicrobial stewardship in Spain: Programs for Optimizing the use of Antibiotics (PROA) in Spanish hospitals. <i>Germes</i> , 2018, 8, 109-112.	0.5	7
107	Deciphering $\beta$ -lactamase-independent $\beta$ -lactam resistance evolution trajectories in <i>Pseudomonas aeruginosa</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 3322-3331.	1.3	27
108	Interplay between Peptidoglycan Biology and Virulence in Gram-Negative Pathogens. <i>Microbiology and Molecular Biology Reviews</i> , 2018, 82, .	2.9	36

#	ARTICLE	IF	CITATIONS
109	Predictors of outcome in patients with severe sepsis or septic shock due to extended-spectrum $\beta$ -lactamase-producing Enterobacteriaceae. <i>International Journal of Antimicrobial Agents</i> , 2018, 52, 577-585.	1.1	36
110	Susceptibility to R-pyocins of <i>Pseudomonas aeruginosa</i> clinical isolates from cystic fibrosis patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2770-2776.	1.3	19
111	The Versatile Mutational Resistome of <i>Pseudomonas aeruginosa</i> . <i>Frontiers in Microbiology</i> , 2018, 9, 685.	1.5	181
112	Ceftolozane/tazobactam for the treatment of multidrug resistant <i>Pseudomonas aeruginosa</i> : experience from the Balearic Islands. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2018, 37, 2191-2200.	1.3	53
113	Meropenem Combined with Ciprofloxacin Combats Hypermutable <i>Pseudomonas aeruginosa</i> from Respiratory Infections of Cystic Fibrosis Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	26
114	MÃ©todos microbiolÃ³gicos para la vigilancia del estado de portador de bacterias multirresistentes. <i>Enfermedades Infecciosas Y MicrobiologÃa ClÃnica</i> , 2017, 35, 667-675.	0.3	24
115	Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum- $\beta$ -lactamase-producing Enterobacteriaceae. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, dkw513.	1.3	46
116	Activity of ceftazidime-avibactam against multidrug-resistance Enterobacteriaceae expressing combined mechanisms of resistance. <i>Enfermedades Infecciosas Y MicrobiologÃa ClÃnica</i> , 2017, 35, 499-504.	0.3	13
117	EpidemiologÃa y mecanismos de resistencia a carbapenemas en <i>Pseudomonas aeruginosa</i> : papel de los clones de alto riesgo en la multirresistencia. <i>Enfermedades Infecciosas Y MicrobiologÃa ClÃnica</i> , 2017, 35, 137-138.	0.3	8
118	Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 726-734.	4.6	367
119	Antibiotic treatment of biofilm infections. <i>Apmis</i> , 2017, 125, 304-319.	0.9	299
120	Understanding the acute inflammatory response to <i>Pseudomonas aeruginosa</i> infection: differences between susceptible and multidrug-resistant strains in a mouse peritonitis model. <i>International Journal of Antimicrobial Agents</i> , 2017, 49, 198-203.	1.1	12
121	Epidemiology and carbapenem resistance mechanisms in <i>Pseudomonas aeruginosa</i> : Role of high-risk clones in multidrug resistance. <i>Enfermedades Infecciosas Y Microbiologia Clinica (English Ed )</i> , 2017, 35, 137-138.	0.2	5
122	Host and Pathogen Biomarkers for Severe <i>Pseudomonas aeruginosa</i> Infections. <i>Journal of Infectious Diseases</i> , 2017, 215, S44-S51.	1.9	116
123	Determining $\beta$ -lactam exposure threshold to suppress resistance development in Gram-negative bacteria. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 1421-1428.	1.3	72
124	WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent $\beta$ -Lactam Enhancer-Activity against <i>Pseudomonas aeruginosa</i> , Including Multidrug-Resistant Metallo- $\beta$ -Lactamase-Producing High-Risk Clones. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	92
125	Synergistic activity of fosfomycin, $\beta$ -lactams and peptidoglycan recycling inhibition against <i>Pseudomonas aeruginosa</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 448-454.	1.3	25
126	Insights into the evolution of the mutational resistome of <i>Pseudomonas aeruginosa</i> in cystic fibrosis. <i>Future Microbiology</i> , 2017, 12, 1445-1448.	1.0	8



#	ARTICLE	IF	CITATIONS
127	Activity of ceftazidimeâ€avibactam against multidrug-resistance Enterobacteriaceae expressing combined mechanisms of resistance. <i>Enfermedades Infecciosas Y Microbiologia Clinica (English Ed)</i> , 2017, 35, 497-502.	0.2	0
128	Diversity and regulation of intrinsic Î²-lactamases from non-fermenting and other Gram-negative opportunistic pathogens. <i>FEMS Microbiology Reviews</i> , 2017, 41, 781-815.	3.9	83
129	Potent Î²-Lactam Enhancer Activity of Zidebactam and WCK 5153 against <i>Acinetobacter baumannii</i> , Including Carbapenemase-Producing Clinical Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	57
130	Prevalence of quinolone resistance mechanisms in Enterobacteriaceae producing acquired AmpC Î²-lactamases and/or carbapenemases in Spain. <i>Enfermedades Infecciosas Y Microbiologia Clinica (English Ed)</i> , 2017, 35, 485-490.	0.2	4
131	Draft Genome Sequences of Four <i>Pseudomonas aeruginosa</i> Isolates Obtained from Patients with Chronic Obstructive Pulmonary Disease. <i>Genome Announcements</i> , 2017, 5, .	0.8	1
132	Interplay among Resistance Profiles, High-Risk Clones, and Virulence in the <i>Caenorhabditis elegans</i> / <i>Pseudomonas aeruginosa</i> Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	39
133	Genomics and Susceptibility Profiles of Extensively Drug-Resistant <i>Pseudomonas aeruginosa</i> Isolates from Spain. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	108
134	Antibiotic resistance and population structure of cystic fibrosis <i>Pseudomonas aeruginosa</i> isolates from a Spanish multi-centre study. <i>International Journal of Antimicrobial Agents</i> , 2017, 50, 334-341.	1.1	20
135	Evolution of the <i>Pseudomonas aeruginosa</i> mutational resistome in an international Cystic Fibrosis clone. <i>Scientific Reports</i> , 2017, 7, 5555.	1.6	117
136	Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study. <i>International Journal of Antimicrobial Agents</i> , 2017, 50, 664-672.	1.1	8
137	Microbiological methods for surveillance of carrier status of multiresistant bacteria. <i>Enfermedades Infecciosas Y Microbiologia Clinica (English Ed)</i> , 2017, 35, 667-675.	0.2	8
138	<i>In Vivo</i> Emergence of Resistance to Novel Cephalosporinâ€Î²-Lactamase Inhibitor Combinations through the Duplication of Amino Acid D149 from OXA-2 Î²-Lactamase (OXA-539) in Sequence Type 235 <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	61
139	Prevalencia en EspaÃ±a de mecanismos de resistencia a quinolonas en enterobacterias productoras de betalactamasas de clase C adquiridas y/o carbapenemasas. <i>Enfermedades Infecciosas Y MicrobiologÃ­a ClÃ­nica</i> , 2017, 35, 487-492.	0.3	8
140	Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum Î²-Lactamaseâ€Producing Enterobacteriaceae: Results From the INCREMENT Cohort. <i>Clinical Infectious Diseases</i> , 2017, 65, 1615-1623.	2.9	43
141	Targeting the permeability barrier and peptidoglycan recycling pathways to disarm <i>Pseudomonas aeruginosa</i> against the innate immune system. <i>PLoS ONE</i> , 2017, 12, e0181932.	1.1	32
142	Impact of multidrug resistance on the pathogenicity of <i>Pseudomonas aeruginosa</i> : in vitro and in vivo studies. <i>International Journal of Antimicrobial Agents</i> , 2016, 47, 368-374.	1.1	30
143	Sequential Treatment of Biofilms with Aztreonam and Tobramycin Is a Novel Strategy for Combating <i>Pseudomonas aeruginosa</i> Chronic Respiratory Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 2912-2922.	1.4	25
144	A Multinational, Preregistered Cohort Study of Î²-Lactam/Î²-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-Î²-Lactamase-Producing Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4159-4169.	1.4	137

#	ARTICLE	IF	CITATIONS
145	Resistance suppression by high-intensity, short-duration aminoglycoside exposure against hypermutable and non-hypermutable <i>Pseudomonas aeruginosa</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3157-3167.	1.3	26
146	Surfactant Protein A Recognizes Outer Membrane Protein OprH on <i>Pseudomonas aeruginosa</i> Isolates From Individuals With Chronic Infection. <i>Journal of Infectious Diseases</i> , 2016, 214, 1449-1455.	1.9	17
147	A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae. <i>Mayo Clinic Proceedings</i> , 2016, 91, 1362-1371.	1.4	89
148	Deciphering the Resistome of the Widespread <i>Pseudomonas aeruginosa</i> Sequence Type 175 International High-Risk Clone through Whole-Genome Sequencing. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 7415-7423.	1.4	99
149	Activity of Ceftazidime-Avibactam against Clinical and Isogenic Laboratory <i>Pseudomonas aeruginosa</i> Isolates Expressing Combinations of Most Relevant $\beta$ -Lactam Resistance Mechanisms. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6407-6410.	1.4	47
150	Impact of AmpC Derepression on Fitness and Virulence: the Mechanism or the Pathway?. <i>MBio</i> , 2016, 7, .	1.8	62
151	Nosocomial dissemination of VIM-2-producing ST235 <i>Pseudomonas aeruginosa</i> in Lithuania. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2016, 35, 195-200.	1.3	21
152	VIM-47, a New Variant of the Autochthonous Metallo- $\beta$ -Lactamase VIM-13 from the Balearic Islands in Spain. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3251-3252.	1.4	3
153	Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1672-1680.	1.3	41
154	Evolution of <i>Pseudomonas aeruginosa</i> Antimicrobial Resistance and Fitness under Low and High Mutation Rates. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1767-1778.	1.4	170
155	Comprehensive clinical and epidemiological assessment of colonisation and infection due to carbapenemase-producing Enterobacteriaceae in Spain. <i>Journal of Infection</i> , 2016, 72, 152-160.	1.7	73
156	Bronchopulmonary infection colonization patterns in Spanish cystic fibrosis patients: Results from a national multicenter study. <i>Journal of Cystic Fibrosis</i> , 2016, 15, 357-365.	0.3	16
157	Genotypic and phenotypic analyses of a <i>Pseudomonas aeruginosa</i> chronic bronchiectasis isolate reveal differences from cystic fibrosis and laboratory strains. <i>BMC Genomics</i> , 2015, 16, 883.	1.2	30
158	Using the Electronic Nose to Identify Airway Infection during COPD Exacerbations. <i>PLoS ONE</i> , 2015, 10, e0135199.	1.1	62
159	Molecular identification of aminoglycoside-modifying enzymes in clinical isolates of <i>Escherichia coli</i> resistant to amoxicillin/clavulanic acid isolated in Spain. <i>International Journal of Antimicrobial Agents</i> , 2015, 46, 157-163.	1.1	36
160	Consenso espaol para la prevenci3n y el tratamiento de la infecci3n bronquial por <i>Pseudomonas aeruginosa</i> en el paciente con fibrosis qu3stica. <i>Archivos De Bronconeumolog3a</i> , 2015, 51, 140-150.	0.4	35
161	The problems of antibiotic resistance in cystic fibrosis and solutions. <i>Expert Review of Respiratory Medicine</i> , 2015, 9, 73-88.	1.0	49
162	Spanish Consensus on the Prevention and Treatment of <i>Pseudomonas aeruginosa</i> Bronchial Infections in Cystic Fibrosis Patients. <i>Archivos De Bronconeumolog3a</i> , 2015, 51, 140-150.	0.4	17

#	ARTICLE	IF	CITATIONS
163	Clinical relevance of <i>Pseudomonas aeruginosa</i> hypermutation in cystic fibrosis chronic respiratory infection. <i>Journal of Cystic Fibrosis</i> , 2015, 14, e1-e2.	0.3	4
164	Mobile Genetic Elements Related to the Diffusion of Plasmid-Mediated AmpC $\beta$ -Lactamases or Carbapenemases from Enterobacteriaceae: Findings from a Multicenter Study in Spain. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5260-5266.	1.4	19
165	Rates of faecal colonization by carbapenemase-producing Enterobacteriaceae among patients admitted to ICUs in Spain: Table 1.. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2916-2918.	1.3	11
166	Role of <i>Pseudomonas aeruginosa</i> Low-Molecular-Mass Penicillin-Binding Proteins in AmpC Expression, $\beta$ -Lactam Resistance, and Peptidoglycan Structure. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3925-3934.	1.4	75
167	<i>N</i> -Acetylcysteine Selectively Antagonizes the Activity of Imipenem in <i>Pseudomonas aeruginosa</i> by an OprD-Mediated Mechanism. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3246-3251.	1.4	16
168	Prospective Multicenter Study of Carbapenemase-Producing Enterobacteriaceae from 83 Hospitals in Spain Reveals High <i>In Vitro</i> Susceptibility to Colistin and Meropenem. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3406-3412.	1.4	130
169	Two Mechanisms of Killing of <i>Pseudomonas aeruginosa</i> by Tobramycin Assessed at Multiple Inocula via Mechanism-Based Modeling. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2315-2327.	1.4	76
170	<i>In vivo</i> evolution of resistance of <i>Pseudomonas aeruginosa</i> strains isolated from patients admitted to an intensive care unit: mechanisms of resistance and antimicrobial exposure. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 3004-3013.	1.3	39
171	The increasing threat of <i>Pseudomonas aeruginosa</i> high-risk clones. <i>Drug Resistance Updates</i> , 2015, 21-22, 41-59.	6.5	475
172	Draft Genome Sequence of the Quorum-Sensing and Biofilm-Producing <i>Pseudomonas aeruginosa</i> Strain Pae221, Belonging to the Epidemic High-Risk Clone Sequence Type 274. <i>Genome Announcements</i> , 2015, 3, .	0.8	5
173	Influence of Virulence Genotype and Resistance Profile in the Mortality of <i>Pseudomonas aeruginosa</i> Bloodstream Infections. <i>Clinical Infectious Diseases</i> , 2015, 60, 539-548.	2.9	153
174	Platelet-Rich Plasma in a Patient with Cerebral Palsy. <i>American Journal of Case Reports</i> , 2015, 16, 469-472.	0.3	14
175	Comparison of Local Features from Two Spanish Hospitals Reveals Common and Specific Traits at Multiple Levels of the Molecular Epidemiology of Metallo- $\beta$ -Lactamase-Producing <i>Pseudomonas</i> spp. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 4992-4992.	1.4	1
176	Microbiological diagnostic procedures for respiratory cystic fibrosis samples in Spain: towards standard of care practices. <i>BMC Microbiology</i> , 2014, 14, 335.	1.3	8
177	Breakpoints for carbapenemase-producing Enterobacteriaceae: Is the problem solved?. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2014, 32, 33-40.	0.3	14
178	<i>Pseudomonas aeruginosa</i> Ceftolozane-Tazobactam Resistance Development Requires Multiple Mutations Leading to Overexpression and Structural Modification of AmpC. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3091-3099.	1.4	197
179	Inhibitor-Resistant TEM- and OXA-1-Producing <i>Escherichia coli</i> Isolates Resistant to Amoxicillin-Clavulanate Are More Clonal and Possess Lower Virulence Gene Content than Susceptible Clinical Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3874-3881.	1.4	23
180	Comparison of Local Features from Two Spanish Hospitals Reveals Common and Specific Traits at Multiple Levels of the Molecular Epidemiology of Metallo- $\beta$ -Lactamase-Producing <i>Pseudomonas</i> spp. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2454-2458.	1.4	11

#	ARTICLE	IF	CITATIONS
181	Genetic and Kinetic Characterization of the Novel AmpC $\beta$ -Lactamases DHA-6 and DHA-7. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6544-6549.	1.4	7
182	Overexpression of MexCD-OprJ Reduces <i>Pseudomonas aeruginosa</i> Virulence by Increasing Its Susceptibility to Complement-Mediated Killing. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2426-2429.	1.4	23
183	A randomized trial of intravenous glutamine supplementation in trauma ICU patients. <i>Intensive Care Medicine</i> , 2014, 40, 539-547.	3.9	33
184	Antimicrobial susceptibility testing in biofilm-growing bacteria. <i>Clinical Microbiology and Infection</i> , 2014, 20, 981-990.	2.8	391
185	Characterization of a novel Zn <sup>2+</sup> -dependent intrinsic imipenemase from <i>Pseudomonas aeruginosa</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2972-2978.	1.3	26
186	Hypermutation in <i>Burkholderia cepacia</i> complex is mediated by DNA mismatch repair inactivation and is highly prevalent in cystic fibrosis chronic respiratory infection. <i>International Journal of Medical Microbiology</i> , 2014, 304, 1182-1191.	1.5	30
187	Minimum information about a biofilm experiment (MIABiE): standards for reporting experiments and data on sessile microbial communities living at interfaces. <i>Pathogens and Disease</i> , 2014, 70, 250-256.	0.8	43
188	The <i>Pseudomonas aeruginosa</i> CreBC Two-Component System Plays a Major Role in the Response to $\beta$ -Lactams, Fitness, Biofilm Growth, and Global Regulation. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 5084-5095.	1.4	56
189	Draft Genome Sequence of Colistin-Only-Susceptible <i>Pseudomonas aeruginosa</i> Strain ST235, a Hypervirulent High-Risk Clone in Spain. <i>Genome Announcements</i> , 2014, 2, .	0.8	4
190	Structure and interaction with phospholipids of a prokaryotic lipoxygenase from <i>Pseudomonas aeruginosa</i> . <i>FASEB Journal</i> , 2013, 27, 4811-4821.	0.2	78
191	Molecular Epidemiology and Multidrug Resistance Mechanisms of <i>Pseudomonas aeruginosa</i> Isolates from Bulgarian Hospitals. <i>Microbial Drug Resistance</i> , 2013, 19, 355-361.	0.9	45
192	Effect of Adequate Single-Drug vs Combination Antimicrobial Therapy on Mortality in <i>Pseudomonas aeruginosa</i> Bloodstream Infections: A Post Hoc Analysis of a Prospective Cohort. <i>Clinical Infectious Diseases</i> , 2013, 57, 208-216.	2.9	135
193	Selective trihydroxyazepane NagZ inhibitors increase sensitivity of <i>Pseudomonas aeruginosa</i> to $\beta$ -lactams. <i>Chemical Communications</i> , 2013, 49, 10983.	2.2	36
194	Prevalence and molecular epidemiology of acquired AmpC $\beta$ -lactamases and carbapenemases in Enterobacteriaceae isolates from 35 hospitals in Spain. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2013, 32, 253-259.	1.3	91
195	Antimicrobial stewardship programs: A public health priority in Spain. The SEIMC-REIPI initiative. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2013, 31, 1-2.	0.3	5
196	Molecular epidemiology and resistance profiles of <i>Clostridium difficile</i> in a tertiary care hospital in Spain. <i>International Journal of Medical Microbiology</i> , 2013, 303, 128-133.	1.5	25
197	Inappropriate use of antibiotics in hospitals: The complex relationship between antibiotic use and antimicrobial resistance. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2013, 31, 3-11.	0.3	68
198	First detection in Europe of the metallo- $\beta$ -lactamase IMP-15 in clinical strains of <i>Pseudomonas putida</i> and <i>Pseudomonas aeruginosa</i> . <i>Clinical Microbiology and Infection</i> , 2013, 19, E424-E427.	2.8	27

#	ARTICLE	IF	CITATIONS
199	Draft Genome Sequence of VIM-2-Producing Multidrug-Resistant <i>Pseudomonas aeruginosa</i> ST175, an Epidemic High-Risk Clone. <i>Genome Announcements</i> , 2013, 1, e0011213.	0.8	9
200	Challenges for accurate susceptibility testing, detection and interpretation of $\beta$ -lactam resistance phenotypes in <i>Pseudomonas aeruginosa</i> : results from a Spanish multicentre study. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 619-630.	1.3	20
201	Characterization of the New AmpC $\beta$ -Lactamase FOX-8 Reveals a Single Mutation, Phe313Leu, Located in the R2 Loop That Affects Ceftazidime Hydrolysis. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 5158-5161.	1.4	8
202	First Report of an OXA-23 Carbapenemase-Producing <i>Acinetobacter baumannii</i> Clinical Isolate Related to Tn2006 in Spain. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 589-591.	1.4	23
203	Biological Markers of <i>Pseudomonas aeruginosa</i> Epidemic High-Risk Clones. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 5527-5535.	1.4	104
204	Epidemiological and Clinical Complexity of Amoxicillin-Clavulanate-Resistant <i>Escherichia coli</i> . <i>Journal of Clinical Microbiology</i> , 2013, 51, 2414-2417.	1.8	13
205	High $\beta$ -Lactamase Levels Change the Pharmacodynamics of $\beta$ -Lactam Antibiotics in <i>Pseudomonas aeruginosa</i> Biofilms. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 196-204.	1.4	69
206	A trade-off between oxidative stress resistance and DNA repair plays a role in the evolution of elevated mutation rates in bacteria. <i>Proceedings of the Royal Society B: Biological Sciences</i> , 2013, 280, 20130007.	1.2	40
207	Clonal Dissemination, Emergence of Mutator Lineages and Antibiotic Resistance Evolution in <i>Pseudomonas aeruginosa</i> Cystic Fibrosis Chronic Lung Infection. <i>PLoS ONE</i> , 2013, 8, e71001.	1.1	69
208	Prospective Multicenter Study of the Impact of Carbapenem Resistance on Mortality in <i>Pseudomonas aeruginosa</i> Bloodstream Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 1265-1272.	1.4	123
209	Intrinsic and Environmental Mutagenesis Drive Diversification and Persistence of <i>Pseudomonas aeruginosa</i> in Chronic Lung Infections. <i>Journal of Infectious Diseases</i> , 2012, 205, 121-127.	1.9	61
210	Spanish Multicenter Study of the Epidemiology and Mechanisms of Amoxicillin-Clavulanate Resistance in <i>Escherichia coli</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 3576-3581.	1.4	49
211	Alterations of OprD in Carbapenem-Intermediate and -Susceptible Strains of <i>Pseudomonas aeruginosa</i> Isolated from Patients with Bacteremia in a Spanish Multicenter Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 1703-1713.	1.4	111
212	Genetic Markers of Widespread Extensively Drug-Resistant <i>Pseudomonas aeruginosa</i> High-Risk Clones. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 6349-6357.	1.4	189
213	Transferable Multidrug Resistance Plasmid Carrying <i>cfr</i> Associated with <i>tet</i> (L), <i>ant(4)-la</i> , and <i>dfpK</i> Genes from a Clinical Methicillin-Resistant <i>Staphylococcus aureus</i> ST125 Strain. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 2139-2142.	1.4	47
214	Characterization of a Novel IMP-28 Metallo- $\beta$ -Lactamase from a Spanish <i>Klebsiella oxytoca</i> Clinical Isolate. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 4540-4543.	1.4	12
215	<i>In Vivo</i> Selection of Moxifloxacin-Resistant <i>Clostridium difficile</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 2788-2789.	1.4	4
216	Antibiotic pressure compensates the biological cost associated with <i>Pseudomonas aeruginosa</i> hypermutable phenotypes <i>in vitro</i> and in a murine model of chronic airways infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 962-969.	1.3	15

#	ARTICLE	IF	CITATIONS
217	Pan- $\beta$ -Lactam Resistance Development in <i>Pseudomonas aeruginosa</i> Clinical Strains: Molecular Mechanisms, Penicillin-Binding Protein Profiles, and Binding Affinities. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 4771-4778.	1.4	138
218	Unusual Diversity of Acquired $\beta$ -lactamases in Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Isolates in a Mexican Hospital. <i>Microbial Drug Resistance</i> , 2012, 18, 471-478.	0.9	15
219	VIM-2-producing Multidrug-Resistant <i>Pseudomonas aeruginosa</i> ST175 Clone, Spain. <i>Emerging Infectious Diseases</i> , 2012, 18, 1235-41.	2.0	59
220	Colonisation and infection due to Enterobacteriaceae producing plasmid-mediated AmpC $\beta$ -lactamases. <i>Journal of Infection</i> , 2012, 64, 176-183.	1.7	45
221	Providing $\beta$ -lactams a helping hand: targeting the AmpC $\beta$ -lactamase induction pathway. <i>Future Microbiology</i> , 2011, 6, 1415-1427.	1.0	61
222	Nontypable <i>Haemophilus influenzae</i> Displays a Prevalent Surface Structure Molecular Pattern in Clinical Isolates. <i>PLoS ONE</i> , 2011, 6, e21133.	1.1	22
223	Evolution and Adaptation in <i>Pseudomonas aeruginosa</i> Biofilms Driven by Mismatch Repair System-Deficient Mutators. <i>PLoS ONE</i> , 2011, 6, e27842.	1.1	53
224	Development of antibiotic resistance and up-regulation of the antimutator gene <i>pfpl</i> in mutator <i>Pseudomonas aeruginosa</i> due to inactivation of two DNA oxidative repair genes ( <i>mutY</i> , <i>mutM</i> ). <i>FEMS Microbiology Letters</i> , 2011, 324, 28-37.	0.7	18
225	A large sustained endemic outbreak of multiresistant <i>Pseudomonas aeruginosa</i> : a new epidemiological scenario for nosocomial acquisition. <i>BMC Infectious Diseases</i> , 2011, 11, 272.	1.3	54
226	Wide Dispersion of ST175 Clone despite High Genetic Diversity of Carbapenem-Nonsusceptible <i>Pseudomonas aeruginosa</i> Clinical Strains in 16 Spanish Hospitals. <i>Journal of Clinical Microbiology</i> , 2011, 49, 2905-2910.	1.8	76
227	Meropenem Penetration into Epithelial Lining Fluid in Mice and Humans and Delineation of Exposure Targets. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 3406-3412.	1.4	40
228	Antagonistic Interactions of <i>Pseudomonas aeruginosa</i> Antibiotic Resistance Mechanisms in Planktonic but Not Biofilm Growth. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 4560-4568.	1.4	58
229	Overexpression of AmpC and Efflux Pumps in <i>Pseudomonas aeruginosa</i> Isolates from Bloodstream Infections: Prevalence and Impact on Resistance in a Spanish Multicenter Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 1906-1911.	1.4	168
230	Environmental Microbiota Represents a Natural Reservoir for Dissemination of Clinically Relevant Metallo- $\beta$ -Lactamases. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 5376-5379.	1.4	55
231	Dynamics of Mutator and Antibiotic-Resistant Populations in a Pharmacokinetic/Pharmacodynamic Model of <i>Pseudomonas aeruginosa</i> Biofilm Treatment. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 5230-5237.	1.4	60
232	<i>Pseudomonas aeruginosa</i> carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 2022-2027.	1.3	132
233	AmpG Inactivation Restores Susceptibility of Pan- $\beta$ -Lactam-Resistant <i>Pseudomonas aeruginosa</i> Clinical Strains. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 1990-1996.	1.4	47
234	Expression of Toll-Like Receptors 2 and 4 is Upregulated During Hospital Admission in Traumatic Patients. <i>Annals of Surgery</i> , 2010, 251, 521-527.	2.1	8

#	ARTICLE	IF	CITATIONS
235	Carrier detection and prenatal diagnosis of congenital adrenal hyperplasia must identify "apparently mild" CYP21A2 alleles which associate neonatal salt-wasting disease. <i>Prenatal Diagnosis</i> , 2010, 30, 758-763.	1.1	11
236	Bacterial hypermutation in cystic fibrosis, not only for antibiotic resistance. <i>Clinical Microbiology and Infection</i> , 2010, 16, 798-808.	2.8	162
237	THE EFFECT OF ELEVATED MUTATION RATES ON THE EVOLUTION OF COOPERATION AND VIRULENCE OF <i>PSEUDOMONAS AERUGINOSA</i> . <i>Evolution; International Journal of Organic Evolution</i> , 2010, 64, 515-521.	1.1	32
238	Assessing the Emergence of Resistance: The Absence of Biological Cost In Vivo May Compromise Fosfomycin Treatments for <i>P. aeruginosa</i> Infections. <i>PLoS ONE</i> , 2010, 5, e10193.	1.1	37
239	NagZ Inactivation Prevents and Reverts $\beta$ -Lactam Resistance, Driven by AmpD and PBP 4 Mutations, in <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 3557-3563.	1.4	61
240	Risk Factors and Prognosis of Nosocomial Bloodstream Infections Caused by Extended-Spectrum- $\beta$ -Lactamase-Producing <i>Escherichia coli</i> . <i>Journal of Clinical Microbiology</i> , 2010, 48, 1726-1731.	1.8	144
241	Differential $\beta$ -lactam resistance response driven by ampD or dacB (PBP4) inactivation in genetically diverse <i>Pseudomonas aeruginosa</i> strains. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1540-1542.	1.3	42
242	Role of changes in the L3 loop of the active site in the evolution of enzymatic activity of VIM-type metallo- $\beta$ -lactamases. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1950-1954.	1.3	29
243	<i>ampG</i> Gene of <i>Pseudomonas aeruginosa</i> and Its Role in $\beta$ -Lactamase Expression. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 4772-4779.	1.4	48
244	Affinity of the New Cephalosporin CXA-101 to Penicillin-Binding Proteins of <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 3933-3937.	1.4	88
245	Anti-biofilm and resistance suppression activities of CXA-101 against chronic respiratory infection phenotypes of <i>Pseudomonas aeruginosa</i> strain PAO1. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1399-1404.	1.3	37
246	Activity of a New Antipseudomonal Cephalosporin, CXA-101 (FR264205), against Carbapenem-Resistant and Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Clinical Strains. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 846-851.	1.4	85
247	Community-Onset Bacteremia Due to Extended-Spectrum $\beta$ -Lactamase-Producing <i>Escherichia coli</i> : Risk Factors and Prognosis. <i>Clinical Infectious Diseases</i> , 2010, 50, 40-48.	2.9	294
248	Activity of a New Cephalosporin, CXA-101 (FR264205), against $\beta$ -Lactam-Resistant <i>Pseudomonas aeruginosa</i> Mutants Selected In Vitro and after Antipseudomonal Treatment of Intensive Care Unit Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 1213-1217.	1.4	96
249	Metallo- $\beta$ -lactamase-producing <i>Pseudomonas putida</i> as a reservoir of multidrug resistance elements that can be transferred to successful <i>Pseudomonas aeruginosa</i> clones. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 474-478.	1.3	105
250	Mutators in cystic fibrosis chronic lung infection: Prevalence, mechanisms, and consequences for antimicrobial therapy. <i>International Journal of Medical Microbiology</i> , 2010, 300, 563-572.	1.5	79
251	Chronic colonization by <i>Pseudomonas aeruginosa</i> of patients with obstructive lung diseases: cystic fibrosis, bronchiectasis, and chronic obstructive pulmonary disease. <i>Diagnostic Microbiology and Infectious Disease</i> , 2010, 68, 20-27.	0.8	72
252	Nosocomial Outbreak of a Non-Cefepime-Susceptible Ceftazidime-Susceptible <i>Pseudomonas aeruginosa</i> Strain Overexpressing MexXY-OprM and Producing an Integron-Borne PSE-1 $\beta$ -Lactamase. <i>Journal of Clinical Microbiology</i> , 2009, 47, 2381-2387.	1.8	35

#	ARTICLE	IF	CITATIONS
253	$\hat{\beta}$ -Lactam Resistance Response Triggered by Inactivation of a Nonessential Penicillin-Binding Protein. <i>PLoS Pathogens</i> , 2009, 5, e1000353.	2.1	258
254	Optical Music Recognition for Scores Written in White Mensural Notation. <i>Eurasip Journal on Image and Video Processing</i> , 2009, 2009, 1-23.	1.7	28
255	<i>Escherichia coli</i> producing SHV-type extended-spectrum $\hat{\beta}$ -lactamase is a significant cause of community-acquired infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 63, 781-784.	1.3	24
256	Inactivation of the <i>hmgA</i> gene of <i>Pseudomonas aeruginosa</i> leads to pyomelanin hyperproduction, stress resistance and increased persistence in chronic lung infection. <i>Microbiology (United Kingdom)</i> , 2009, 155, 1050-1057.	0.7	124
257	Azithromycin in <i>Pseudomonas aeruginosa</i> Biofilms: Bactericidal Activity and Selection of <i>nfxB</i> Mutants. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 1552-1560.	1.4	73
258	Detection of the Novel Extended-Spectrum $\hat{\beta}$ -Lactamase OXA-161 from a Plasmid-Located Integron in <i>Pseudomonas aeruginosa</i> Clinical Isolates from Spain. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 5288-5290.	1.4	25
259	Inactivation of the Glycoside Hydrolase NagZ Attenuates Antipseudomonal $\hat{\beta}$ -Lactam Resistance in <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 2274-2282.	1.4	65
260	Extended-spectrum $\hat{\beta}$ -lactamase-producing <i>Escherichia coli</i> in Spain belong to a large variety of multilocus sequence typing types, including ST10 complex/A, ST23 complex/A and ST131/B2. <i>International Journal of Antimicrobial Agents</i> , 2009, 34, 173-176.	1.1	164
261	Nosocomial Spread of Colistin-Only-Sensitive Sequence Type 235 <i>Pseudomonas aeruginosa</i> Isolates Producing the Extended-Spectrum $\hat{\beta}$ -Lactamases GES-1 and GES-5 in Spain. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 4930-4933.	1.4	91
262	Chronic <i>Pseudomonas aeruginosa</i> Infection in Chronic Obstructive Pulmonary Disease. <i>Clinical Infectious Diseases</i> , 2008, 47, 1526-1533.	2.9	235
263	Benefit of Having Multiple <i>ampD</i> Genes for Acquiring $\hat{\beta}$ -Lactam Resistance without Losing Fitness and Virulence in <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 3694-3700.	1.4	91
264	Genetic Adaptation of <i>Pseudomonas aeruginosa</i> to the Airways of Cystic Fibrosis Patients Is Catalyzed by Hypermutation. <i>Journal of Bacteriology</i> , 2008, 190, 7910-7917.	1.0	219
265	<i>Pseudomonas aeruginosa</i> RsmA Plays an Important Role during Murine Infection by Influencing Colonization, Virulence, Persistence, and Pulmonary Inflammation. <i>Infection and Immunity</i> , 2008, 76, 632-638.	1.0	92
266	Characterization of plasmids encoding blaESBL and surrounding genes in Spanish clinical isolates of <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 63, 60-66.	1.3	66
267	Community Infections Caused by Extended-Spectrum $\hat{\beta}$ -Lactamase-Producing <i>Escherichia coli</i> . <i>Archives of Internal Medicine</i> , 2008, 168, 1897.	4.3	333
268	Chronic Respiratory Infections by Mucoic Carbapenemase-Producing <i>Pseudomonas aeruginosa</i> Strains, a New Potential Public Health Problem. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 2285-2286.	1.4	12
269	Characterization of the New Metallo- $\hat{\beta}$ -Lactamase VIM-13 and Its Integron-Borne Gene from a <i>Pseudomonas aeruginosa</i> Clinical Isolate in Spain. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 3589-3596.	1.4	71
270	Novel Phosphorylcholine-Containing Protein of <i>Pseudomonas aeruginosa</i> Chronic Infection Isolates Interacts with Airway Epithelial Cells. <i>Journal of Infectious Diseases</i> , 2008, 197, 465-473.	1.9	52



#	ARTICLE	IF	CITATIONS
271	Inactivation of the Mismatch Repair System in <i>Pseudomonas aeruginosa</i> Attenuates Virulence but Favors Persistence of Oropharyngeal Colonization in Cystic Fibrosis Mice. <i>Journal of Bacteriology</i> , 2007, 189, 3665-3668.	1.0	48
272	Improvement in Growth after Two Years of Growth Hormone Therapy in Very Young Children Born Small for Gestational Age and without Spontaneous Catch-Up Growth: Results of a Multicenter, Controlled, Randomized, Open Clinical Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 3095-3101.	1.8	44
273	Influence of High Mutation Rates on the Mechanisms and Dynamics of In Vitro and In Vivo Resistance Development to Single or Combined Antipseudomonal Agents. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 2574-2581.	1.4	34
274	Biological cost of hypermutation in <i>Pseudomonas aeruginosa</i> strains from patients with cystic fibrosis. <i>Microbiology (United Kingdom)</i> , 2007, 153, 1445-1454.	0.7	85
275	Increased Susceptibility to Colistin in Hypermutable <i>Pseudomonas aeruginosa</i> Strains from Chronic Respiratory Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 4531-4532.	1.4	8
276	Molecular Epidemiology and Mechanisms of Carbapenem Resistance in <i>Pseudomonas aeruginosa</i> Isolates from Spanish Hospitals. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 4329-4335.	1.4	161
277	P880 Single-step selection of double mutations leading to high antibiotic-resistance in hyper-mutable <i>Pseudomonas aeruginosa</i> . <i>International Journal of Antimicrobial Agents</i> , 2007, 29, S227-S228.	1.1	0
278	Coevolution with viruses drives the evolution of bacterial mutation rates. <i>Nature</i> , 2007, 450, 1079-1081.	13.7	263
279	Molecular epidemiology of methicillin-resistant <i>Staphylococcus aureus</i> in Majorcan hospitals: high prevalence of the epidemic clone EMRSA-15. <i>Clinical Microbiology and Infection</i> , 2007, 13, 599-605.	2.8	22
280	Nosocomial spread of <i>Pseudomonas aeruginosa</i> producing the metallo- $\beta$ -lactamase VIM-2 in a Spanish hospital: clinical and epidemiological implications. <i>Clinical Microbiology and Infection</i> , 2007, 13, 1026-1029.	2.8	35
281	PBP3 inhibition elicits adaptive responses in <i>Pseudomonas aeruginosa</i> . <i>Molecular Microbiology</i> , 2006, 62, 84-99.	1.2	97
282	Efficacy and Potential for Resistance Selection of Antipseudomonal Treatments in a Mouse Model of Lung Infection by Hypermutable <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 975-983.	1.4	77
283	Characterization of a Large Outbreak by CTX-M-1-Producing <i>Klebsiella pneumoniae</i> and Mechanisms Leading to In Vivo Carbapenem Resistance Development. <i>Journal of Clinical Microbiology</i> , 2006, 44, 2831-2837.	1.8	126
284	Stepwise Upregulation of the <i>Pseudomonas aeruginosa</i> Chromosomal Cephalosporinase Conferring High-Level $\beta$ -Lactam Resistance Involves Three AmpD Homologues. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 1780-1787.	1.4	164
285	Hypermutation in natural bacterial populations: consequences for medical microbiology. <i>Reviews in Medical Microbiology</i> , 2005, 16, 25-32.	0.4	6
286	Antimicrobial therapy for pulmonary pathogenic colonisation and infection by <i>Pseudomonas aeruginosa</i> in cystic fibrosis patients. <i>Clinical Microbiology and Infection</i> , 2005, 11, 690-703.	2.8	134
287	Contribution of clonal dissemination and selection of mutants during therapy to <i>Pseudomonas aeruginosa</i> antimicrobial resistance in an intensive care unit setting. <i>Clinical Microbiology and Infection</i> , 2005, 11, 887-892.	2.8	38
288	Hypermutation Is a Key Factor in Development of Multiple-Antimicrobial Resistance in <i>Pseudomonas aeruginosa</i> Strains Causing Chronic Lung Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 3382-3386.	1.4	274

#	ARTICLE	IF	CITATIONS
289	Molecular Mechanisms of $\hat{\text{I}}^2$ -Lactam Resistance Mediated by AmpC Hyperproduction in <i>Pseudomonas aeruginosa</i> Clinical Strains. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 4733-4738.	1.4	146
290	CTX-M-10 Linked to a Phage-Related Element Is Widely Disseminated among Enterobacteriaceae in a Spanish Hospital. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 1567-1571.	1.4	70
291	Detection and Susceptibility Testing of Hypermutable <i>Pseudomonas aeruginosa</i> Strains with the Etest and Disk Diffusion. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 2665-2672.	1.4	64
292	Lack of Association between Hypermutation and Antibiotic Resistance Development in <i>Pseudomonas aeruginosa</i> Isolates from Intensive Care Unit Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 3573-3575.	1.4	60
293	Hypermutation and the Preexistence of Antibiotic-Resistant <i>Pseudomonas aeruginosa</i> Mutants: Implications for Susceptibility Testing and Treatment of Chronic Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 4226-4233.	1.4	138
294	Epidemiological relatedness of methicillin-resistant <i>Staphylococcus aureus</i> from a tertiary hospital and a geriatric institution in Spain. <i>Clinical Microbiology and Infection</i> , 2004, 10, 339-342.	2.8	16
295	Evaluation of the NCCLS Extended-Spectrum $\hat{\text{I}}^2$ -Lactamase Confirmation Methods for <i>Escherichia coli</i> with Isolates Collected during Project ICARE. <i>Journal of Clinical Microbiology</i> , 2003, 41, 3142-3146.	1.8	59
296	Genes Encoding TEM-4, SHV-2, and CTX-M-10 Extended-Spectrum $\hat{\text{I}}^2$ -Lactamases Are Carried by Multiple <i>Klebsiella pneumoniae</i> Clones in a Single Hospital (Madrid, 1989 to 2000). <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 500-510.	1.4	178
297	Epidemiology of Extended-Spectrum $\hat{\text{A}}$ -Lactamase-Producing Enterobacter Isolates in a Spanish Hospital during a 12-Year Period. <i>Journal of Clinical Microbiology</i> , 2002, 40, 1237-1243.	1.8	119
298	TEM-71, a Novel Plasmid-Encoded, Extended-Spectrum $\hat{\text{I}}^2$ -Lactamase Produced by a Clinical Isolate of <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 2000-2003.	1.4	12
299	Mutation and Evolution of Antibiotic Resistance: Antibiotics as Promoters of Antibiotic Resistance?. <i>Current Drug Targets</i> , 2002, 3, 345-349.	1.0	57
300	Mechanisms of Decreased Susceptibility to Cefpodoxime in <i>Escherichia coli</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 3829-3836.	1.4	79
301	The mismatch repair system ( <i>mutS</i> , <i>mutL</i> and <i>uvrD</i> genes) in <i>Pseudomonas aeruginosa</i> : molecular characterization of naturally occurring mutants. <i>Molecular Microbiology</i> , 2002, 43, 1641-1650.	1.2	243
302	Characterization of the GO system of <i>Pseudomonas aeruginosa</i> . <i>FEMS Microbiology Letters</i> , 2002, 217, 31-35.	0.7	47
303	Performance of the VITEK2 system for identification and susceptibility testing of routine Enterobacteriaceae clinical isolates. <i>International Journal of Antimicrobial Agents</i> , 2001, 17, 371-376.	1.1	18
304	Validation of the VITEK2 and the advance expert system with a collection of enterobacteriaceae harboring extended spectrum or inhibitor resistant $\hat{\text{I}}^2$ -lactamases. <i>Diagnostic Microbiology and Infectious Disease</i> , 2001, 41, 65-70.	0.8	17
305	Characterization of Clinical Isolates of <i>Klebsiella pneumoniae</i> from 19 Laboratories Using the National Committee for Clinical Laboratory Standards Extended-Spectrum $\hat{\text{A}}$ -Lactamase Detection Methods. <i>Journal of Clinical Microbiology</i> , 2001, 39, 2864-2872.	1.8	170
306	Prevalence of extended-spectrum $\hat{\text{I}}^2$ -lactamases in group-1 $\hat{\text{I}}^2$ -lactamase-producing isolates. <i>Clinical Microbiology and Infection</i> , 2001, 7, 278-282.	2.8	6

#	ARTICLE	IF	CITATIONS
307	Nucleotide Sequence and Characterization of a Novel Cefotaxime-Hydrolyzing $\hat{\beta}$ -Lactamase (CTX-M-10) Isolated in Spain. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 616-620.	1.4	106
308	Nontuberculous Mycobacteria in Patients with Cystic Fibrosis. <i>Clinical Infectious Diseases</i> , 2001, 32, 1298-1303.	2.9	83
309	Molecular Characterization of FOX-4, a New AmpC-Type Plasmid-Mediated $\hat{\beta}$ -Lactamase from an <i>Escherichia coli</i> Strain Isolated in Spain. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 2549-2553.	1.4	50
310	Outbreak of a Multiresistant <i>Klebsiella pneumoniae</i> Strain in an Intensive Care Unit: Antibiotic Use as Risk Factor for Colonization and Infection. <i>Clinical Infectious Diseases</i> , 2000, 30, 55-60.	2.9	160
311	OXA-24, a Novel Class D $\hat{\beta}$ -Lactamase with Carbapenemase Activity in an <i>Acinetobacter baumannii</i> Clinical Strain. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 1556-1561.	1.4	226
312	Pneumococcal psoas abscess: report of two cases. <i>Clinical Microbiology and Infection</i> , 2000, 6, 168-169.	2.8	9
313	High Frequency of Hypermutable <i>Pseudomonas aeruginosa</i> in Cystic Fibrosis Lung Infection. <i>Science</i> , 2000, 288, 1251-1253.	6.0	1,322
314	Evaluation of the Wider System, a New Computer-Assisted Image-Processing Device for Bacterial Identification and Susceptibility Testing. <i>Journal of Clinical Microbiology</i> , 2000, 38, 1339-1346.	1.8	48
315	Ampicillin-Sulbactam and Amoxicillin-Clavulanate Susceptibility Testing of <i>Escherichia coli</i> Isolates with Different $\hat{\beta}$ -Lactam Resistance Phenotypes. <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 862-867.	1.4	27
316	MICROSATELLITE MARKERS IN THE INDIRECT ANALYSIS OF THE STEROID 21-HYDROXYLASE GENE. , 1997, 17, 429-434.		16
317	Analysis of steroid 21-hydroxylase gene mutations in the Spanish population. <i>Human Genetics</i> , 1995, 96, 198-204.	1.8	112
318	Evolution of <i>Pseudomonas aeruginosa</i> Pathogenicity: From Acute to Chronic Infections. , 0, , 433-444.		10
319	Duration of Treatment for <i>Pseudomonas aeruginosa</i> Bacteremia: a Retrospective Study. <i>Infectious Diseases and Therapy</i> , 0, , .	1.8	6
320	Comparison of Ceftolozane/Tazobactam Infusion Regimens in a Hollow-Fiber Infection Model against Extensively Drug-Resistant <i>Pseudomonas aeruginosa</i> Isolates. <i>Microbiology Spectrum</i> , 0, , .	1.2	1
321	CARB-ES-19 Multicenter Study of Carbapenemase-Producing <i>Klebsiella pneumoniae</i> and <i>Escherichia coli</i> From All Spanish Provinces Reveals Interregional Spread of High-Risk Clones Such as ST307/OXA-48 and ST512/KPC-3. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	20